Preclinical development of a therapeutic anticancer antibody to c-Met [ 2016 - 2017 ]

Research Grant

Researchers: Prof Terrance Johns (Principal investigator) ,  A/Pr Christoph Hagemeyer

Brief description Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.

Funding Amount $AUD 435,530.30

Funding Scheme Development Grants

Notes Development Grant